Seeking Alpha HealthcareOriginal article
Evolent projects 2027 revenue growth of more than 25% with 2027 adjusted EBITDA midpoint at or above $150m
EarningsPositive
AI Analysis
Summary
Evolent has issued 2027 revenue guidance projecting growth exceeding 25% with adjusted EBITDA midpoint at or above $150 million.
Financial Highlights
Revenue
more than 25% growth projected for 2027
Guidance
2027 adjusted EBITDA midpoint at or above $150m
Importance:5/10
Sentiment:
0.60
guidancerevenue_projectionEBITDAfinancial_outlook
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on August 6, 2026 4:18 PM